Expanding the Potential of CAR T Cell Therapy

The XCART technology platform was designed to utilize an established screening technique to identify polypeptide domains that selectively bind to the unique B-cell receptor (BCR) on the surface of an individual lymphoma patient’s malignant B-cell clones. This BCR-selective targeting domain is engineered into the antigen-binding domain of a chimeric antigen receptor (CAR), creating the possibility of a CAR T treatment that should only recognize a given patient’s malignant B-cell clones. We believe our personalized CAR T therapies have the potential to offer cancer patients substantial benefits over the existing standard of care and currently approved CAR T therapies.

Internal Development Programs

Program Indication Preclinical Phase 1 Phase 2 Phase 3 Next Catalyst
XCART™ Platform B-Cell Non-Hodgkin Lymphoma
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
  • 5/2020: Research and Development Collaboration: Scripps Research

Upcoming

  • 2020: FDA INTERACT Meeting
  • 2020: Secure additional academic and development collaborations
  • 2021: Expected IND Filing
  • Goal to secure industry collaboration

XCART Targets the B-Cell Receptor as a Patient- and Tumor-Specific Neoantigen in B-Cell Lymphoma

An expected result for XCART is limited off-tumor toxicities, such as B-cell aplasia. Xenetic’s clinical development program will seek to confirm the early preclinical results, and to demonstrate a more attractive safety profile than existing therapies.

Selective Targeting of Unique BCRs by XCART™ CAR T is Differentiated from Current Anti-CD19 CAR T Approaches

Benefits of XCART

Demonstrated proof-of-mechanism and preclinical evidence of target specificity

  • XCART constructs can target patient- and tumor-specific neoantigens
  • Potential to address various target and tumor types
  • Proprietary cell-based CAR screening technology
  • Proprietary autocrine technology licensed from Scripps (originating in Richard Lerner’s lab)
  • Compatible with current up- and down-stream CAR T manufacturing processes
  • Applicable to wide range of CAR T constructs
  • Enables rapid construction of functional CARs & TCRs

Learn more about our lead XCART™ program